Blogs written by our own experts or selected members of the drug discovery community.
Detecting tumour DNA through liquid biopsies marks the new frontier in oncology, providing a wealth of critical data for drug development research.
With availability limited and lab facilities not evenly spread across the UK, it is important to make well-informed decisions on the kind of lab space you need early on, because these choices can have consequences further down the line.
With availability limited and lab facilities not evenly spread across the UK, it is important to make well-informed decisions on the kind of lab space you need early on, because these choices can have consequences further down the line.
With availability limited and lab facilities not evenly spread across the UK, it is important to make well-informed decisions on the kind of lab space you need early on, because these choices can have consequences further down the line.
Throughout my career, my radiopharmaceutical work has spanned all stages of development, from target biology, distribution, and dosimetry to translational modelling and clinical use. Despite this varied experience, I have mostly been driven by one objective: ensuring that preclinical data do more than simply demonstrate scientific promise. A core part of my role here at MDC is helping innovators design studies that answer the questions that investors and regulators care about most, early enough to enable decision-making, drive clear outcomes, and reduce risk in radiopharmaceutical development.
A new wave of medicines has emerged in recent years, to supplement the established small and large molecule platforms. These complex medicines will become as important as traditional small molecule drugs in the coming years, with market values of hundreds of billions of pounds.
Offering clarity to the scope of the term ‘complex medicines’
With availability limited and lab facilities not evenly spread across the UK, it is important to make well-informed decisions on the kind of lab space you need early on, because these choices can have consequences further down the line.
Read what some of our female scientists have to say about working in science
See how we can help support you with your next drug discovery project.
Speak to us
